The Conversation (0)
Cellectar Receives USPTO Notice of Allowance for Patent Covering Use of CLR 131 in Multiple Myeloma
Feb. 07, 2018 09:07AM PST
Biotech Investing
Cellectar Biosciences (Nasdaq:CLRB), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, announces that the United States Patent and Trademark Office has issued a notice of allowance for U.S. Patent Application No. 15/095,641, entitled “Alkylphosphocholine Analogs for Multiple Myeloma Imaging and Therapy,” which covers a …
Cellectar Biosciences (Nasdaq:CLRB), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, announces that the United States Patent and Trademark Office has issued a notice of allowance for U.S. Patent Application No. 15/095,641, entitled “Alkylphosphocholine Analogs for Multiple Myeloma Imaging and Therapy,” which covers a method of use for CLR 131, the company’s lead radiotherapeutic Phospholipid Drug Conjugate™ (PDC™) in multiple myeloma.
As quoted in the press release:
“This patent allowance enhances our intellectual property estate and underscores the novelty of CLR 131 for the treatment of multiple myeloma, a life-threatening disease with high unmet medical need,” said James Caruso, chief executive officer of Cellectar Biosciences. “Importantly, upon issuance, this patent will extend our coverage into the mid-2030s.”